Lung Cancer
Lung Cancer
5 years ago

Anamorelin for advanced non-small-cell lung cancer with cachexia: Systematic review and meta-analysis

Cancer anorexia-cachexia syndrome (CACS) is characterized by involuntary weight loss. CACS is commonly observed in advanced non-small-cell lung cancer (NSCLC), and it leads to a poor quality of life (QOL). No effective standard treatment exists for this condition. However, anamorelin has reportedly caused improvement in patients with several cancers. Materials and methods We conducted a quantitative meta-analysis to explore the efficacy of anamorelin for treating CACS in patients with NSCLC. We systematically searched CENTRAL, MEDLINE, EMBASE, CINAHL, and OvidSP. We pooled the data and calculated and compared total body weight (TBW), lean body mass (LBM), overall survival (OS), hand grip strength (HGS), QOL, and adverse events (AEs) between patients treated with anamorelin (anamorelin group) and those not (placebo group). Result Six randomized controlled trials included 1641 patients with NSCLC. Both TBW and LBM were significantly increased in the anamorelin group compared to the placebo group (mean differences [MD] 1.78, 95%CI: 1.28–2.28, p < 0.00001; MD 1.10, 95%CI: 0.35–1.85, p =0.004, respectively). The groups showed no difference in OS or HGS (hazard ratio 0.99, 95%CI: 0.85–1.14, p =0.84; MD 0.52, 95% CI: −0.09–1.13, p =0.09, respectively). Anamorelin significantly improved the QOL (standardized MD 0.19, 95%CI: 0.08–0.30, p =0.0006). The frequency of any AEs and grade 3 or 4 AEs were not significantly different between groups (risk ratio[RR] 1.03, 95%CI: 0.95–1.10, p =0.49; RR 0.86, 95%CI: 0.48–1.54, p =0.62). Conclusion This analysis demonstrated that anamorelin represents a promising treatment option for CACS in patients with advanced NSCLC.

Publisher URL: www.sciencedirect.com/science

DOI: S0169500217304026

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.